Payment overview · 2025
General Payments
$609.55
14 reported records · 10 companies
Healthcare provider profile · identity verified
Sergio Patton, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHARLOTTE, NC · NPI 1104321538
Verified facts
What the public records show
CMS Open Payments records show Sergio Patton, MD received $609.55 in general payments during 2025 across 14 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 24.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 357 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $147.49 | 24.2% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $141.48 | 23.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $104.27 | 17.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.89 | 9.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.48 | 7.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.91 | 6.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.55 | 3.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.20 | 3.0% | 1 | 2025 |
| The Binding Site Inc. | Unresolved — no canonical attribution shown | $17.73 | 2.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $15.55 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $609.55 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $147.49 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $141.48 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $104.27 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.89 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $47.48 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.91 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $37.91 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| Freelite Normalized: freelite |
Device | The Binding Site Inc. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $15.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 357 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 197 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
357 | 64 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
197 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
108 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 770 | 217 |
| Amlodipine Besylate | Amlodipine Besylate | 571 | 164 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 390 | 128 |
| Jardiance | Empagliflozin | 357 | 64 |
| Ezetimibe | Ezetimibe | 270 | 82 |
| Losartan Potassium | Losartan Potassium | 257 | 80 |
| Telmisartan | Telmisartan | 235 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 207 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 197 | 50 |
| Ozempic | Semaglutide | 197 | 32 |
| Omeprazole | Omeprazole | 193 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 36 |
| Metformin Hcl Er | Metformin Hcl | 128 | 44 |
| Metformin Hcl | Metformin Hcl | 122 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 119 | 33 |
| Furosemide | Furosemide | 115 | 39 |
| Eliquis | Apixaban | 108 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 105 | 28 |
| Gabapentin | Gabapentin | 102 | 36 |
| Farxiga | Dapagliflozin Propanediol | 93 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 20 |
| Trulicity | Dulaglutide | 78 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 30 |
| Simvastatin | Simvastatin | 71 | 25 |
| Spironolactone | Spironolactone | 70 | 23 |
| Allopurinol | Allopurinol | 67 | 18 |
| Carvedilol | Carvedilol | 66 | 18 |
| Lisinopril | Lisinopril | 64 | 18 |
| Alendronate Sodium | Alendronate Sodium | 63 | 19 |
| Atenolol | Atenolol | 61 | 18 |
| Candesartan Cilexetil | Candesartan Cilexetil | 59 | 18 |
| Glipizide | Glipizide | 59 | 22 |
| Potassium Chloride | Potassium Chloride | 57 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 22 |
| Famotidine | Famotidine | 55 | 12 |
| Meloxicam | Meloxicam | 52 | 25 |
| Trazodone Hcl | Trazodone Hcl | 52 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 14 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Alprazolam | Alprazolam | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 11 |
| Montelukast Sodium | Montelukast Sodium | 40 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 11 |
| Sertraline Hcl | Sertraline Hcl | 34 | 12 |
| Valsartan | Valsartan | 34 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Torsemide | Torsemide | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Prednisone | Prednisone | 31 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 27 | 12 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Nexletol | Bempedoic Acid | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 20 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 18 |
| Clonidine | Clonidine | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Eplerenone | Eplerenone | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Kerendia | Finerenone | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Celecoxib | Celecoxib | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $609.55 · 14 records | Bayer Healthcare Pharmaceuticals Inc. | APTIMA, FREESTYLE LIBRE 3, Freelite, JARDIANCE, Kerendia, NURTEC ODT, Ozempic, REPATHA, UBRELVY, WaveWriter Alpha Prime 16, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error